Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Predictive factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer.
Authors
AhReum Lim
Division of Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
AhReum Lim , Jwa Hoon Kim , Myung Han Hyun , Yeul Hong Kim , Soohyeon Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
DOI
10.1200/JCO.2022.40.4_suppl.085
Abstract #
85
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX/FOLFIRI plus cetuximab.
First Author: S.P. Somashekhar
Poster
2016 Gastrointestinal Cancers Symposium
Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.
First Author: Stefano Cascinu
Poster
2015 Gastrointestinal Cancers Symposium
Randomized phase II studies comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab or cetuximab with FOLFOX or FOLFIRI.
First Author: Marc Van Den Eynde
Poster
2014 ASCO Annual Meeting
Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.
First Author: Volker Heinemann